Skip to main
  1. Stocks
  2. Surgery Partners
  3. Forecast
SGRY

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 0%
Buy 29%
Hold 71%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners is viewed as fundamentally attractive because its scaled ambulatory surgery center platform sits in an underpenetrated market where payors are pushing more procedures to lower-cost outpatient settings, supporting durable volume growth. Its 120 consolidated facilities, leadership in high-acuity specialties, and management’s confidence in sustaining double-digit EBITDA growth are reinforced by Medicare rule changes that could expand the addressable market and by continued OR and physician recruitment investment. The company’s strategic value is further highlighted by takeover interest at about 14.2x to 14.4x FY27 EBITDA, alongside Bain’s 39% ownership support and a credible path to higher growth without changing its core fee-for-service model.

Bears say

Surgery Partners is facing a structurally pressured operating backdrop where mature fee-for-service providers are contending with higher staffing costs, turnover, and reimbursement that generally lags, which can compress margins even as demand and patient volume have recently recovered. The sustainability of that rebound remains uncertain, while more onerous CMS reimbursement and regulatory provisions for home health and Medicare Advantage underscore a broader payer environment that can remain restrictive. On top of that, the company’s outlook is burdened by managed care and Medicare dependence, integration and recruitment risk, labor inflation, revenue concentration, and meaningful balance sheet leverage, with the downside case implying roughly a 10.7x FY27 adjusted EBITDA-MI multiple.

Surgery Partners (SGRY) has been analyzed by 7 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 29% recommend Buy, 71% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Surgery Partners (SGRY) Analyst Forecast & Price Prediction

Get the latest Surgery Partners (SGRY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Surgery Partners (SGRY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Hold based on their latest research and market trends.

According to 7 analysts, Surgery Partners (SGRY) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Surgery Partners (SGRY) Analyst Forecast & Price Prediction

Get the latest Surgery Partners (SGRY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Surgery Partners (SGRY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SGRY stock data and trends